Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494366 | 0.88 | TEAD1 (0.50) | KCNA5KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL4286026 | 0.88 | HPGD (0.49) | KCNA5KMT2AALDH1A1L3MBTL1HPGD | |
| SCHEMBL4286428 | 0.88 | HCRTR1 (0.47) | KCNA5ALDH1A1RAB9AHTT | |
| SCHEMBL4281983 | 0.88 | L3MBTL1 (0.48) | KCNA5KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL4295216 | 0.87 | KMT2A (0.49) | KMT2AMEN1ALDH1A1L3MBTL1HRH3 | |
| SCHEMBL4285825 | 0.86 | KCNA5 (0.49) | KCNA5MEN1ALDH1A1HRH3 | |
| SCHEMBL4287625 | 0.86 | KDM4E (0.50) | KMT2AALDH1A1HRH3HTTLMNA | |
| SCHEMBL4294542 | 0.85 | KDM4E (0.49) | ALDH1A1L3MBTL1HRH3NPSR1 | |
| SCHEMBL4287459 | 0.84 | KMT2A (0.49) | KMT2AMEN1ALDH1A1HRH3RAB9A | |
| SCHEMBL4286463 | 0.83 | GPR119 (0.49) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KCNA5 867/4885KMT2A 1049/4885MEN1 1254/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KCNA5 867/4885KMT2A 1049/4885MEN1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.